Your browser doesn't support javascript.
loading
Impact of COVID-19 on Tuberculosis Prevention and Treatment in Canada: A Multicenter Analysis of 10 833 Patients.
Geric, Coralie; Saroufim, Mariane; Landsman, David; Richard, Jonathan; Benedetti, Andrea; Batt, Jane; Brode, Sarah K; Ahmad Khan, Faiz.
Afiliación
  • Geric C; McGill International TB Centre, Centre for Outcomes Research & Evaluation, Research Institute of the McGill University Health Centre, Montreal, Canada.
  • Saroufim M; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada.
  • Landsman D; McGill International TB Centre, Centre for Outcomes Research & Evaluation, Research Institute of the McGill University Health Centre, Montreal, Canada.
  • Richard J; MAP Center for Urban Health Solution, Li Ka Shing Knowledge Institute, St Michael's Hospital, Unity Health Toronto, Toronto, Canada.
  • Benedetti A; Montreal Chest Institute, McGill University Health Centre, Montreal, Canada.
  • Batt J; McGill International TB Centre, Centre for Outcomes Research & Evaluation, Research Institute of the McGill University Health Centre, Montreal, Canada.
  • Brode SK; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada.
  • Ahmad Khan F; Division of Respirology TB Program and Keenan Research Center for Biomedical Sciences, St Michael's Hospital, Unity Health Toronto, Toronto, Canada.
J Infect Dis ; 225(8): 1317-1320, 2022 04 19.
Article en En | MEDLINE | ID: mdl-34919700
ABSTRACT
We assessed the COVID-19 pandemic's impact on treatment of latent tuberculosis, and of active tuberculosis, at 3 centers in Montreal and Toronto, using data from 10 833 patients (8685 with latent tuberculosis infection, 2148 with active tuberculosis). Observation periods prior to declarations of COVID-19 public health emergencies ranged from 219 to 744 weeks, and after declarations, from 28 to 33 weeks. In the latter period, reductions in latent tuberculosis infection treatment initiation rates ranged from 30% to 66%. At 2 centers, active tuberculosis treatment rates fell by 16% and 29%. In Canada, cornerstone measures for tuberculosis elimination weakened during the COVID-19 pandemic.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Tuberculosis / Tuberculosis Latente / COVID-19 Tipo de estudio: Clinical_trials Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: J Infect Dis Año: 2022 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Tuberculosis / Tuberculosis Latente / COVID-19 Tipo de estudio: Clinical_trials Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: J Infect Dis Año: 2022 Tipo del documento: Article País de afiliación: Canadá